Abstract
Tetracyclines are a class of antibiotics which could play a therapeutic role in several neurological disorders. Minocycline, extensively studied in animal models, decreased the size of ischaemic and haemorrhagic infarct. In Parkinsons disease models minocycline protected the nigrostriatal pathway, and in Huntingtons disease and motoneuron disease models delayed the progression of disease extending the lifespan. Finally, in human diseases such as stroke and multiple sclerosis tetracyclines seem to play some neuroprotective role. The main biological effects of tetracyclines are the inhibition of microglial activation, the attenuation of apoptosis, and the suppression of reactive oxygen species production. These mechanisms are involved in the pathogenesis of several neurodegenerative disorders. Several reports showed that minocycline reduced mitochondrial Ca2+ uptake, stabilized mitochondrial membranes, and reduced the release into the cytoplasm of apoptotic factors. Other effects include upregulation of mitochondrial bcl-2 (an antiapoptotic protein), direct scavenging of reactive oxygen species, and inhibition of mitogen activated protein kinases. It is still unclear which of these mechanisms plays the pivotal role in neuroprotective properties of tetracyclines. The anti-apoptotic effect of tetracyclines probably involves the mitochondrion. The major target for tetracyclines in neurodegeneration could lie within the complex network that links mitochondria, oxidative stress, poly (ADP-ribose) polymerase-1 and apoptosis. Here, we review the neuroprotective effects of tetracyclines in animal models and in human disease, and we focus on their possible mechanism(s) of action, with special regard to mitochondrial dysfunction in neurodegeneration.
Keywords: Mitochondria, Neurodegeneration, PARP-1, ROS, Tetracyclines
CNS & Neurological Disorders - Drug Targets
Title: Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
Volume: 8 Issue: 3
Author(s): D. Orsucci, V. Calsolaro, M. Mancuso and G. Siciliano
Affiliation:
Keywords: Mitochondria, Neurodegeneration, PARP-1, ROS, Tetracyclines
Abstract: Tetracyclines are a class of antibiotics which could play a therapeutic role in several neurological disorders. Minocycline, extensively studied in animal models, decreased the size of ischaemic and haemorrhagic infarct. In Parkinsons disease models minocycline protected the nigrostriatal pathway, and in Huntingtons disease and motoneuron disease models delayed the progression of disease extending the lifespan. Finally, in human diseases such as stroke and multiple sclerosis tetracyclines seem to play some neuroprotective role. The main biological effects of tetracyclines are the inhibition of microglial activation, the attenuation of apoptosis, and the suppression of reactive oxygen species production. These mechanisms are involved in the pathogenesis of several neurodegenerative disorders. Several reports showed that minocycline reduced mitochondrial Ca2+ uptake, stabilized mitochondrial membranes, and reduced the release into the cytoplasm of apoptotic factors. Other effects include upregulation of mitochondrial bcl-2 (an antiapoptotic protein), direct scavenging of reactive oxygen species, and inhibition of mitogen activated protein kinases. It is still unclear which of these mechanisms plays the pivotal role in neuroprotective properties of tetracyclines. The anti-apoptotic effect of tetracyclines probably involves the mitochondrion. The major target for tetracyclines in neurodegeneration could lie within the complex network that links mitochondria, oxidative stress, poly (ADP-ribose) polymerase-1 and apoptosis. Here, we review the neuroprotective effects of tetracyclines in animal models and in human disease, and we focus on their possible mechanism(s) of action, with special regard to mitochondrial dysfunction in neurodegeneration.
Export Options
About this article
Cite this article as:
Orsucci D., Calsolaro V., Mancuso M. and Siciliano G., Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease, CNS & Neurological Disorders - Drug Targets 2009; 8 (3) . https://dx.doi.org/10.2174/187152709788680689
DOI https://dx.doi.org/10.2174/187152709788680689 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development)
Current Pharmaceutical Design Potential Phytotherapeutic Approaches for the Treatment of Alzheimer’s Disease: An Overview
Current Traditional Medicine Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Nanotubes at Neural and Immune Synapses
Current Medicinal Chemistry Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research Pharmacomimetics of Exercise: Novel Approaches for Hippocampally- Targeted Neuroprotective Agents
Current Medicinal Chemistry Protective Substances Against Zinc-Induced Neuronal Death after Ischemia:Carnosine as a Target for Drug of Vascular Type of Dementia
Recent Patents on CNS Drug Discovery (Discontinued) The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Screening for Inhibitors of Tau Polymerization
Current Alzheimer Research Animal Models in Neurology: Drawbacks and Opportunities
Current Pharmaceutical Design α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Lipid Alterations in the Earliest Clinically Recognizable Stage of Alzheimers Disease: Implication of the Role of Lipids in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Nanoparticle-Based Therapy in Genomics
Current Drug Metabolism Peptide Agonists and Antagonists with Potential Application in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Regulatory Cascade of Neuronal Loss and Glucose Metabolism
CNS & Neurological Disorders - Drug Targets